.7%; p < 0.0005) and lower in the over 60 year olds (55.1 vs. 59.6%; p = 0.5). Conclusion: Genotype 1b, historically the most prevalent in Italy, is still predominant; however, when comparing the two time periods, a cohort effect evidencing the increasing prevalence of genotype 1b among elderly patients was revealed.
The distribution of HCV genotypes varies significantly with geography [6] [7] [8] ; genotypes 1, 2 and 3 are found throughout the world whereas the other genotypes are relatively restricted to certain geographic regions of Africa, Asia and the Middle East [9] [10] [11] . In particular, genotype 4 is prevalent in north and central Africa and in the Middle East [12] [13] [14] , genotype 5 prevails in South Africa [15] and in some areas of central France [16] , and genotype 6 is frequent in the Far East, especially in China [17] [18] [19] . A clear correlation between age and genotype incidence has also been found, i.e. a greater prevalence of 1b and 2a/2c in older patients and 1a and 3a in younger individuals [20] [21] [22] , suggesting the involvement of intravenous drug use.
In some countries, a change in prevalence from HCV genotype 1 to genotypes 3 and 4 over the last decade has been reported; this is presumably ascribable to the eradication of transfusion-associated infections, continuous increase in intravenous drug use, increase in immigration patterns and the spread of unsafe sexual practices in sexually active age groups [23] . In Italy, around half of cases are of the 1b type, with 2a/2c being the next prevalent subtype. Whether or not a north-south distribution gradient exists is as yet unconfirmed; however, in the country as a whole, the incidence of genotype 3a appears to be increasing and certainly merits investigation [24, 25] .
Hence, the aim of this study was to provide up-to-date information on the prevalence of the various HCV genotypes and any age-or gender-related correlations in a group of HCV-positive patients from the Naples metropolitan area.
Materials and Methods

Study Population and Sample Collection
The population analysed in this study comprised 5,550 consecutively recruited outpatients resident in the metropolitan area of Naples, Italy, and referred to the National Tumour Institute 'Fondazione G. Pascale' Transfusion Service Virology Clinic in Naples between January 2009 and June 2011.
In the study cohort, 2,830 patients (51.0%) were females and 2,720 (49.0%) males; the mean age of female patients was 47.5 years (range , and that of males was 50.5 years (range 18-83). Data on risk factors for HCV were only available for some patients and were therefore not considered in this study. Patients with autoimmune disorders were excluded to prevent interference with serological testing.
Of the 5,550 enrolled subjects, 436 (7.8%) were found to be positive for anti-HCV. Two hundred and fifty-five (58.0%) members of this population were also positive for HCV RNA and were therefore included in this study.
Of the 181 patients excluded from the study, 73 (40.3%) were found to be HCV RNA negative, while in 108 (59.7%), serum was insufficient for HCV RNA determination. No significant gender or age differences were found between the study group and the excluded patients.
Viral genotyping was performed on the 255 included subjects, a total of 118 males (46.0%) and 137 females (54.0%); both gender groups featured a mean age of 52.5 years (range 21-84).
In order to analyse possible changes in the distribution of HCV genotypes in the metropolitan area of Naples, another group of 176 consecutive anti-HCV-positive/HCV RNA-positive samples, collected between January 2006 and December 2008, also from subjects living in the metropolitan area of Naples and referred to the same clinic, were assessed as above. There were no differences in the pattern of sampling or testing used in the two considered periods .
Viral genotyping was performed on sample subjects, a total of 89 males (50.6%) and 87 females (49.4%); both gender groups featured a mean age of 53.5 years (range 25-82).
Serology and Molecular Analysis
All the plasma samples pertaining to both study groups were analysed for the presence of anti-HCV antibodies by means of the Vitros ECi test (OrthoClinical Diagnostics), used according to the manufacturers' instructions.
The OrthoClinical Vitros ECi test employs chemiluminescent technology in which a light signal is created by a positive antibodyantigen reaction in direct proportion to the amount of antibody present. Results are reported as signal to cutoff. Results greater than or equal to 1.00 are considered reactive for HCV antibodies. The specificity and sensitivity of the test are, respectively, 99.97 and 100%.
Only repeatedly anti-HCV-reactive samples were subsequently tested for the presence of HCV RNA via the COBAS Ampliprep/COBAS Taqman HCV 48 (Roche Diagnostics System Inc.), which exploits a polymerase chain reaction in real time. The linear range of quantification of the test was 1.50 × 10 1 to 6.90 × 10 7 HCV RNA IU/ml, using the accuracy acceptance criterion of ±0.3 log 10 . The specificity of the test was 100%, and its detection limit was 15 IU/ml.
HCV genotyping was performed using the Versant HCV Genotype Assay 2.0 LiPA test (Siemens Healthcare Diagnostics), which involves the amplification and hybridization of viral genome fragments, the latter by means of genotype-specific probes adsorbed onto nitrocellulose strips. The various steps were performed by Auto-LiPA, a fully automated system for complete genotyping. The specificity and sensitivity of this test are, respectively, 96 and 99.4%, and its detection limit is 15 IU/ml.
Statistical Analysis
Statistical analysis of the data was performed using SPSS for Windows, version 7.5. Frequency tables were analysed using χ 2 tests, with Pearson correlations being used to assess the significance of the correlation between the categorical variables. Differences in the mean ages for the genotypes and subtypes were analysed using Student's t test. In all tests, p values <0.05 were regarded as statistically significant.
The odds estimation of genotype distribution in relation to gender and age in the two periods was performed by multiple logistic regression analysis.
Results
The distribution of the genotypes among the patients in the two periods of analysis is reported in tables 1 and 2 . All type 3 cases were found to be subtype 3a, and no genotypes 5 and 6 were detected. Genotype 1b was the most common in both periods, but its prevalence decreased from 2006-2008 to 2009-2011, being 51.8 and 48.3%, respectively. This was accompanied by a parallel increase in the rate of genotype 2 (including subtype 2a/2c and non-subtypable genotype 2) from 27.9 to 31.7%. In our study, subtypes 1 * and 2 * (not further classified) represent the third and fourth largest groups, respectively, in the 3-year period 2009-2011 (9.4 and 8.2%, respectively). Subtype 3a decreased from 6.8 to 4.7%, and genotype 1a also decreased, from 7.9 to 4.7%. Although the exact classification of not-further-subtypable genotype 1 (1 * ) is not clear, its frequency (4.6 and 9.4%, respectively, in the 2006-2008 and 2009-2011 populations) could have significantly changed the distribution of this genotype during the last 6 years. Genotype 4 was the most stable of all over time, with an overall prevalence of 1.1%.
We then analysed the gender-related differences observed between the subtypes ( tables 1 , 2 ). Genotype 1b was more frequently observed in females than in males in both periods analysed (39.3% of 89 males vs. Infected patients showed a different distribution of risk factors for HCV acquisition in the main genotype subgroups ( tables 3 , 4 ). Dental therapy, blood transfusion and surgery were the most frequent risk factors for HCV acquisition in genotypes 1 and 2, whereas intravenous drug abuse and tattooing were prevalent in genotype 3a. No data were available for genotype 4.
An increase in the prevalence of dental therapy as a major risk factor for genotype 1 was observed from 2006-2008 to 2009-2011, being 28.4 and 45.3%, respectively. This was accompanied by a parallel decrease in the rate of transmission via blood transfusion from 16.9 to 7.5%.
In order to compare the prevalence of HCV genotypes according to age during these two periods, the patients were categorized into 5 age groups, as shown in tables 5 and 6 . The distribution varied significantly according to age in both analysis periods. In both time frames, genotype 1b was more common in the over-50 age group than Values represent numbers with percentages in parentheses. If more than one risk factor was present, the one most likely to have caused infection was assigned. Values represent numbers with percentages in parentheses. If more than one risk factor was present, the one most likely to have caused infection was assigned. By analysing the distribution of HCV genotypes in the two periods, we observed that the prevalence of patients with genotype 1b in patients aged 51-60 years was higher in 2006-2008 than in 2009-2011 (76.9 vs. 37.7%; p < 0.0005) and lower in the patients over 60 years old (55.1 vs. 59.6%; p = 0.5; fig. 1 ). A similar distribution was also evident for genotype 3a ( fig. 2 ) ; in the period 2006-2008, this genotype was present only in the under-50 age group, while in the period 2009-2011 it was also seen in the 51-60 years age group ( fig. 2 ) . The number of patients infected with genotype 4 was small but appears to have increased in older patients over the last 5 years ( tables 5 , 6 ).
The significance of the different distributions of HCV genotypes in the two periods was then analysed using multivariable logistic regression in which the prevalence of different genotypes was independently associated with gender and age. We demonstrated that all the differences in HCV genotype prevalence were significant and not related to variability of gender or age group (data not shown).
Discussion
The data from the present study seem to suggest that there has been no substantial change in the overall epidemiology of HCV genotypes in the metropolitan area of Naples over the last 5 years. Genotype 1b, historically the most prevalent, both in this area and throughout Italy, remains so (48.3%), followed by genotype 2a/2c (23.5%). Genotypes 1a and 3a, on the other hand, are considerably less common (both 4.7%) in the geographical area in question, as compared to the findings from studies performed in other regions of northern Italy (9.3 and 12.7%, respectively), even though the exact classification of 'not further classified' genotype 1 (1 * ), which some studies group together with subtype 1a [20] , is still unclear.
The gender distribution shows a clear frequency among females and males of genotype 1b (54.0% of 134 females vs. 41.5% of 118 males; p < 0.05), while genotype 3a is completely absent in males (10.2 vs. 0%; p< 0.0005).
Considering the age group distribution, genotypes 1b and 2 (including subtype 2a/2c and non-subtypable gen- otype 2) were seen considerably more frequently in older patients, while 3a was particularly common in their younger counterparts. This appears to confirm the reduced risk of transfusion-related transmission and the 'stratification' of genotypes associated with risk factors reported in the literature [20, 26] . Moreover, our data seem to confirm the existence of two transmission patterns of HCV genotypes in Italy as previously reported by other authors [24] ; the first pattern is characterized by infections with subtypes 1b and 2a/2c, mainly in adults over 60 years of age, consistent with past health care-related practices, and the second by subtypes 3 and 4, mainly found in the 31-60 years age group, consistent with intravenous drug abuse and immigration. Many published studies have suggested direct links between genotypes 1b and 2a/2c and iatrogenic infections and/or blood transfusions, and between genotypes 1a and 3 and drug addiction [27] . Our study showed clearly that blood transfusions now play a minor role in causing new infections because of the strict screening procedures, whereas the risk of acquiring HCV through dental therapy seems to have increased in the last 3 years.
Moreover, a direct correlation between genotype and age, with a high frequency of genotypes 1b and 2a/2c in older patients and genotypes 1a and 3a in younger patients, has also been observed [23] .
Comparative analysis of the two 3-year periods (2006-2008 and 2009-2011) revealed an interesting trend in genotype 1b. This has become more and more frequent among elderly patients in recent years, which is presumably ascribable to a cohort effect. It may be that these patients, having been infected several years ago, when genotype 1b was likely to be the only one present in the population and the rate of new infection was high, have maintained their old infection, among a pool of younger carriers infected with genotypes 3a and 1a. In fact, a high frequency of genotypes 3a and 1a in under-40-year-old subjects was observed in the period 2006-2008. This was not confirmed in the 3-year period 2009-2011, when we observed a dramatic reduction in the prevalence of genotypes 3a and 1a in subjects under 30 years of age. Multivariate analysis showed that these differences in the prevalence of genotypes 3a and 1b in the two 3-year periods were independently associated with any variability in gender and/or age group.
Recently, the emergence of genotype 4 in some Mediterranean countries, especially Spain, Greece and Italy, has been documented [24, 28, 29] . The spread of genotype 4 has been correlated with intravenous drug use and active immigration from endemic areas in the Middle East and Africa. However, these findings seem not to be confirmed in our geographical area. Genotype 4 appears to have remained stable over the last 6 years, with a low average prevalence of 1.1%.
In conclusion, it could be hypothesized that 1b is the original 'resident' genotype, spread in the 1970s, especially through iatrogenic transmission. The introduction of anti-HCV screening tests in the 1990s may have dramatically reduced this risk, thereby generating the cohort effect we now observe. In the meantime, the spread of intravenous drug use could have led to a new wave of HCV infection among young people, with an increase of new 'emergent' genotypes (3a, 1a and 4) [30] . More recently, presumably due to the diffusion of different types of drugs not necessarily linked to intravenous practice, even this transmission chain has been curtailed.
Although HCV 1b still remains the prevailing genotype, a future evaluation of new 'emerging' subtypes will be necessary.
